ASX Share rice
Tue 04 Aug 2020 - 03:30:pm (Sydney)

IBX Share Price

IMAGION BIOSYSTEMS LIMITEDIBXHealth Care Equipment & Services

IBX Company Information

Name:

Imagion Biosystems Limited

Sector:

Healthcare

Industry:

Diagnostics & Research

Address:

10355 Science Center Drive San Diego CA United States 92121

Phone:

855 564 5264

Pres & CEO:

Mr. Robert Romeo Proulx

Company Sec. & Non Exec. Director:

Ms. Jovanka Naumoska

Vice-Pres of Research & Pre- Clinical Dev:

Dr. Marie Zhang

Company Overview:

Imagion Biosystems Limited provides medical imaging technologies to detect and eliminate cancer. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company engages in the research and development of its MagSense system to detect HER2 breast cancers. It uses MagSense technology that is based on superparamagnetic relaxometry for early cancer detection, cancer staging, and therapeutic monitoring. The company was founded in 1996 and is based in San Diego, California.

IBX Share Price Information

Shares Issued:

761.78M

Market Capitalisation:

$37.33M

Revenue (TTM):

$2.49M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.018

Profit Margin:

-1.3785

Operating Margin (TTM):

$-1.36

Return On Assets (TTM):

$-0.42

Return On Equity (TTM):

$-1

Quarterly Revenue Growth (YOY):

0.101

Gross Profit(TTM):

$220.99K

Diluted Earnings Per Share (TTM):

$-0.01

IBX CashFlow Statement

CashFlow Date:

2019-12-31

Investments:

$-12,353

Change To Liabilities:

$-298,909

Total Cashflow From Investing Activities:

$-12,353

Net Borrowings:

$-35,395

Net Income:

$-3,432,506

Total Cash From Operating Activities:

$-4,182,045

Depreciation:

$141.99K

Change To Account Receivables:

$24.19K

Sale Purchase Of Stock:

$-13,305

Capital Expenditures:

$12.35K

IBX Income Statement

Income Date:

2019-12-31

Income Before Tax:

$-3,432,506

Net Income:

$-3,432,506

Gross Profit:

$410.85K

Operating Income:

$-5,469,657

Interest Expense:

$9.16K

Total Revenue:

$410.85K

Total Operating Expenses:

$5.88M

IBX Balance Sheet

Balance Sheet Date:

2019-12-31

Total Liabilities:

$1.90M

Total Stockholder Equity:

$2.97M

Other Current Liabilities:

$33.99K

Total Assets:

$4.87M

Common Stock:

$36.90M

Other Current Assets:

$73.14K

Retained Earnings:

$-34,645,541

Cash:

$3.40M

Total Current Liabilities:

$1.28M

Property - Plant & Equipment:

$1.30M

Net Tangible Assets:

$2.97M

Total Current Assets:

$3.57M

Net Receivables:

$71

Short-Term Investments:

$1.30M

Accounts Payable:

$708.91K

Non Currrent Assets (Other):

$1.30M

Short-Term Investments:

$1.30

Non Current Liabilities Total:

$615.02K

IBX Share Price History

IBX News

13 Nov, 2019
MELBOURNE, Australia, Nov. 12, 2019 /PRNewswire/ -- Imagion Biosystems Limited (IBX.AX), a company dedicated to improving healthcare through the earlier detection of cancer, has been issued patent #320872 from the Government of India Patent Office for the Company's core intellectual property related to detection, measurement and imaging using targeted magnetic nanoparticles. The newly issued patent adds India to the Company's existing global market coverage which includes Australia, Canada, China, Israel, Japan, Russia, and the U.S. The term of the India patent extends to 2030. The number of people receiving a diagnosis of cancer in India is expected to increase from 1.15 million in 2018 to 1.41 million by 2026, according to the International Agency for Research on Cancer.
30 Oct, 2019
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
16 Oct, 2019
MELBOURNE, Australia, Oct. 16, 2019 /PRNewswire/ -- Imagion Biosystems Limited (IBX.AX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, today announces appointments to its newly established Scientific Advisory Board. Chaired by Dr John Hazle, Chair of the Department of Imaging Physics at the MD Anderson Cancer Center and previously a non-executive Director of IBX until June 2019, the Scientific Advisory Board brings together a group of highly qualified experts in disciplines ranging from oncology, medical imaging, nanotechnology and clinical trial design.
24 Sep, 2019
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
05 Aug, 2019
If you're interested in Imagion Biosystems Limited (ASX:IBX), then you might want to consider its beta (a measure of...